Eigen Therapeutics

Eigen Therapeutics, a biotechnology company, is dedicated to revolutionizing cancer treatment with its mission to make therapies that facilitate the detection and elimination of cancer. Specializing in the development of "priming" therapies, Eigen aims to enhance the effectiveness of targeted therapies by addressing cancer heterogeneity. This involves making cancer cells more susceptible and bolstering healthy cells' resilience to treatment. The company is in the process of constructing a high-throughput discovery platform that utilizes proprietary machine learning algorithms to identify novel associations, new drug classes, and potential therapies. This innovative intersection of biology and engineering encompasses in-house developed robotic systems, laboratory operations software, and machine learning analysis pipelines, all with the goal of ultimately saving more lives. Having received its Venture Round investment from ZAKA VC on 11 March 2024, Eigen Therapeutics, founded in 2021, is headquartered in the United States. The company's slogan, "We help targeted therapies hit their mark," encapsulates its commitment to advancing the field of biotechnology and transforming cancer treatment.